# Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain

> **NCT01316744** · PHASE3 · UNKNOWN · sponsor: **University of Glasgow** · enrollment: 214 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** ketamine hydrochloride
- **OTHER:** pharmacogenomic studies
- **OTHER:** questionnaire administration
- **PROCEDURE:** assessment of therapy complications
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT01316744
- **Lead sponsor:** University of Glasgow
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-04
- **Primary completion:** 2011-10
- **Final completion:** —
- **Target enrollment:** 214 (ESTIMATED)
- **Last updated:** 2011-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01316744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01316744, "Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01316744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*